Sartorius Stedim stock gained 3.14% as analysts assess recovery

Published on 10/07/2026 at 13:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius Stedim stock advanced 3.14% to EUR 216.600 on October 6, 2026, while 14 analysts held a Strong Buy consensus. H1 revenue reached EUR 1,527 million.

Flatlay mit Laborpipetten, Filtermembranen, Schutzhandschuhen und ISIN-Karte FR0013154002 — Sartorius Stedim Biotech Flatlay mit Laborpipetten, Filtermembranen, Aktien-Zertifikat und ISIN-Karte, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim stock gained 3.14% to EUR 216.600 on Euronext Paris on October 6, 2026, with the company valued at EUR 21.1 billion. The move put the share price back near the upper end of its recent trading range as analysts focused on a recovery in bioprocessing demand.

Analysts keep recovery case alive

According to finanzen.ch on October 6, 2026, RBC Capital Markets maintained an Outperform rating and a EUR 210 price target after reviewing the effects of US tariff refunds, the MatTek acquisition and currency movements. The target is below the October 6 reference price, making the RBC view more cautious than the broader analyst panel.

Investing.com lists a Strong Buy consensus from 14 analysts, including 13 Buy ratings and one Hold rating. The average 12-month target is EUR 237.29, with a high of EUR 262 and a low of EUR 210; measured against EUR 216.600, the average target stands 9.55 percent above the reference price.

H1 figures set the operating test

For the first half of 2026, Sartorius Stedim reported revenue of EUR 1,527 million, EBITDA of EUR 463.7 million and an EBITDA margin of 31.4 percent, according to Ideal Investor. The figures give the stock a concrete operating base after the strong share-price recovery.

The company reaffirmed 2026 guidance for constant-currency revenue growth of 6 to 10 percent and an underlying EBITDA margin slightly above 31 percent in its Sartorius Stedim investor-relations page. Consumables remain the main growth driver, while equipment demand is expected to stay stable, leaving execution and customer investment as the central operating tests.

Third-quarter date approaches

Investing.com gives October 22, 2026 as the next earnings date. That report will show whether the 31.4 percent first-half EBITDA margin and the 6 to 10 percent full-year growth framework are carrying into the second half.

Stock rises to EUR 216.600

Sartorius Stedim was last quoted at EUR 216.600 on Euronext Paris on October 6, 2026, up from a previous close of EUR 210.000, with 15,603 shares traded and a market capitalization of EUR 21.1 billion.